# Biogen (BIIB) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/BIIB
## Company Profile
- Ticker: BIIB
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: CNS, Rare Disease
## Stock Data
- Close: 222.89 USD
- Market cap: 27878316803.11 USD
- Last updated: 2026-10-06
## Business Overview
Biogen is a large biotechnology company focused on neuroscience and rare disease, with a long history in multiple sclerosis and other neurological disorders. Its business combines commercial products with a major research engine.
## Why The Stock Is Moving

As of Oct 6, 2026, BIIB closed down 0.31% at $222.89. No new same-company headline was identified in the current news window.

## Geographic Base

Biogen is headquartered in the United States and listed on NASDAQ. It sits in large-cap biotechnology with a neuroscience identity.

## Business Model

The company generates value through product sales, lifecycle management, and ongoing R&D in difficult CNS and rare-disease areas. Investors watch launch execution, pipeline progress, and franchise durability.

## Landscape Position

Biogen occupies one of the most important large-cap neuroscience positions in biotech. It is far less binary than a small-cap name, but major pipeline and label events still matter a lot.

## Future Catalysts

- Biogen’s catalysts are lecanemab execution, rare-disease growth, and any CNS pipeline update that helps extend the franchise. The market will watch whether the commercial base keeps broadening.

## Recent News
- 2026-10-02 15:20 EST — [Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus](https://biopharmsignal.com/news/BIIB/biogen-s-litifilimab-demonstrates-rapid-and-durable-efficacy-in-new-52-week-phas-bb06832e) — Source: Biogen
- 2026-09-17 20:15 EST — [Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN](https://biopharmsignal.com/news/BIIB/phase-3-pediatric-empaveli-data-published-in-clinical-journal-of-the-american-so-b88a0071) — Source: Biogen
- 2026-09-16 06:00 EST — [LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease](https://biopharmsignal.com/news/BIIB/leqembi-pen-subcutaneous-formulation-of-leqembi-approved-in-japan-for-the-treatm-89d36d6e) — Source: Biogen
- 2026-09-03 23:30 EST — [Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)](https://biopharmsignal.com/news/BIIB/stoke-therapeutics-and-biogen-present-long-term-clinical-data-that-support-the-d-caea5702) — Source: Biogen
- 2026-09-03 04:00 EST — [LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China](https://biopharmsignal.com/news/BIIB/leqembi-lecanemab-subcutaneous-formulation-as-an-initiation-treatment-for-early--ff189c91) — Source: Biogen